PDK inhibitors

PDK1 (Phosphoinositide-dependent kinase-1) also known as PDPK1 (3-phosphoinositide dependent protein kinase-1) is a serine/threonine protein kinase, which functions as a master kinase to phosphorylate and activate a subgroup of the AGC family kinases such as PKB/Akt, PKC, S6K, SGK, and RSK, thus, playing a pivotal role in the PI3K/Akt signaling pathway.

Kat.nr. Produktnamn Information Citeringar av produktanvändning Produktvalideringar
S1274 BX-795 BX-795 är en potent och specifik PDK1-hämmare med IC50 på 6 nM, 140- och 1600-faldigt mer selektiv för PDK1 än PKA respektive PKC i cellfria analyser. Samtidigt, jämfört med GSK3β, observerades mer än 100-faldig selektivitet för PDK1. BX-795 modulerar autophagy via att hämma ULK1. BX-795 är också en potent TBK1-hämmare som blockerar både TBK1 och IKKε med IC 50-värden på 6 nM respektive 41 nM.
Cancer Res, 2025, 10.1158/0008-5472.CAN-25-1791
Cell Rep, 2025, 44(7):115972
EMBO J, 2024, 10.1038/s44318-024-00244-9
Verified customer review of BX-795
S0983 JX06 JX06 är en selektiv kovalent hämmare av PDK1 i celler. Denna förening hämmar dosberoende PDK1, PDK2 och PDK3 med IC50 0,049 μM, 0,101 μM respektive 0,313 μM.
Biochem Biophys Res Commun, 2021, 587:153-159
S8615 Sodium Dichloroacetate (DCA) DCA (Sodium Dichloroacetate), en specifik hämmare av pyruvate dehydrogenase kinase (PDK) med IC50-värden på 183 respektive 80 μM för PDK2 och PDK4, har visat sig dereprimera Na+-K+-2Cl- cotransporter och en mitokondriell kaliumjonkanal-axel. Sodium Dichloroacetate ökar bildningen av reactive oxygen species (ROS), utlöser apoptosis i cancerceller och hämmar tumörtillväxt.
bioRxiv, 2025, 2025.04.03.647023
bioRxiv, 2025, 2025.08.24.671623
bioRxiv, 2025, 2023.08.11.552890
S2949 KPLH1130 KPLH1130 är en specifik hämmare av pyruvate dehydrogenase kinase (PDK) som blockerar makrofagpolarisering och dämpar proinflammatoriska svar.

PDK1 protein is composed of two well-characterized functional domains: (1) the N-terminal serine/threonine kinase domain of the AGC family, and (2) the C-terminal Pleckstrin homology (PH) domain that interacts with high affinity with both PtdIns(3,4,5)P3 and PtdIns(3,4)P2 as well as other phosphoinositides such as PtdIns(4,5)P2. PDK1 is ubiquitously expressed and constitutively active in mammalian cells. In addition to being able to constitutively phosphorylate substrates, PDK1 also works in an inducible manner in response to specific stimuli. Without stimuli, the catalytic activity of PDK1 is kept under control by limiting its access to targets, whereas upon stimulation, the different PDK1 substrates are converted into forms that can be recognized, phosphorylated and activated by PDK1. PDK1 regulates as much as 23 growth-factor-stimulated AGC kinases, containing protein kinase B (PKB/Akt) isoforms, p70 ribosomal protein S6 kinase (S6K) isoforms, p90 ribosomal protein S6 kinases (RSK), serum- and glucocorticoid-induced protein kinase (SGK) isoforms, and several protein kinase C (PKC) isoforms, by phosphorylating at the serine/threonine residues in their T-loop. [1]

The autophosphorylation of PDK1 at Ser241 in the T-loop or activation loop contributes to the catalytic activity of PDK1 upon substrate binding, and several other phosphorylation sites have also been proposed to contribute to the regulation of PDK1 activity. Upon growth factor stimulation and PtdIns(3,4,5)P3 production, both PKB/Akt and PDK1 translocate to the plasma membrane via the specific interaction of their PH domains with newly generated PtdIns(3,4,5)P3, where PDK1 could then readily phosphorylate and activate PKB/Akt, allowing PKB/Akt to phosphorylate downstream targets such as Foxo1. The mTORC1 or mTORC2 mediated phosphorylation of the hydrophobic motif of AGC kinases is essential for PDK1-mediated activation. This is achieved by creating a docking site for the binding of PDK1 to facilitate the phosphorylation of the kinases at its T-loop by PDK1. Moreover, the interaction of the hydrophobic motif binding pocket (PIF pocket) of PDK1 with the phosphorylated hydrophobic motif in the substrate induces the allosteric activation of PDK1. [1]

Therefore, through targeting a particular set of these AGC kinases, PDK1 play a critical role in regulating a wide variety of physiological processes including cell growth, proliferation, survival, development, and metabolism. PDK1 knockout mice die during early embryonic development, and the PDK1 dominant negative mutants knock-in mice are also shown to be embryonically lethal. A series of tissue-specific conditional knockout mice lacking PDK1 also confirm both the implication of PDK1 in mediating metabolic responses to insulin as well as in promoting cell viability, which proposes that selective activation of PDK1 might be a good strategy for the treatment of diabetes. However, PDK1 overexpression and amplification of the PDK1 gene are common occurrences in breast cancer and acute myeloid leukaemia. PDK1 also displays an epistatic relationship with the lipid phosphatase PTEN in the migration and malignant transformation of lymphocytes and in regulating nervous system development. Moreover, PTEN heterozygous mice expressing reduced levels of PDK1 are markedly protected from developing a wide range of tumors, indicating that PDK1 is a key effector in mediating tumorigenesis resulting from loss of PTEN and further validating PDK1 as a valuable anticancer target for the development of specific inhibitors. [1]